Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608216 · ClinicalTrials.gov registry record · Phase 1
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
A Phase 1 study of Metastatic Breast Cancer and Breast Neoplasm, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02608216: Active Phase 1 study of Metastatic Breast Cancer and Breast Neoplasm, sponsored by University of Pennsylvania.
NCT02608216 is a Phase 1 study of Metastatic Breast Cancer and Breast Neoplasm that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 20 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02608216, a Phase 1 study of Metastatic Breast Cancer and Breast Neoplasm, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT).
Primary Outcome
Measure changes in \[18F\]FLT uptake in metastatic tumors before and during treatment with ribociclib (LEE011) only and associate these changes with response to ribociclib (LEE011)/paclitaxel therapy.
Conditions Studied
Interventions
- DRUG ribociclib
- DRUG paclitaxel
- DEVICE PET/CT
- DRUG [18F]FLT
Study Locations (1)
Pennsylvania
- University of Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-11 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What the registry record for NCT02608216 still lists
NCT02608216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which ribociclib is the first listed.
NCT02608216 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02608216 about?
NCT02608216 is a clinical study titled "[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer". In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT).
What is the current status of trial NCT02608216?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-11. Estimated completion is 2026-11.
What conditions does trial NCT02608216 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Breast Neoplasm, Rb+ Breast Cancer.
What interventions are being tested in trial NCT02608216?
The interventions under investigation include: ribociclib (DRUG), paclitaxel (DRUG), PET/CT (DEVICE), [18F]FLT (DRUG).
Who is sponsoring clinical trial NCT02608216?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02608216 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02608216's enrollment target sits among peer trials
20 119th of 139 higher than 18 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia